215 related articles for article (PubMed ID: 36250888)
1. Creating MHC-Restricted Neoantigens with Covalent Inhibitors That Can Be Targeted by Immune Therapy.
Hattori T; Maso L; Araki KY; Koide A; Hayman J; Akkapeddi P; Bang I; Neel BG; Koide S
Cancer Discov; 2023 Jan; 13(1):132-145. PubMed ID: 36250888
[TBL] [Abstract][Full Text] [Related]
2. Molecular basis for antibody recognition of multiple drug-peptide/MHC complexes.
Maso L; Rajak E; Bang I; Koide A; Hattori T; Neel BG; Koide S
Proc Natl Acad Sci U S A; 2024 May; 121(22):e2319029121. PubMed ID: 38781214
[TBL] [Abstract][Full Text] [Related]
3. A covalent inhibitor of K-Ras(G12C) induces MHC class I presentation of haptenated peptide neoepitopes targetable by immunotherapy.
Zhang Z; Rohweder PJ; Ongpipattanakul C; Basu K; Bohn MF; Dugan EJ; Steri V; Hann B; Shokat KM; Craik CS
Cancer Cell; 2022 Sep; 40(9):1060-1069.e7. PubMed ID: 36099883
[TBL] [Abstract][Full Text] [Related]
4. Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing.
Leclerc M; Mezquita L; Guillebot De Nerville G; Tihy I; Malenica I; Chouaib S; Mami-Chouaib F
Front Immunol; 2019; 10():1505. PubMed ID: 31333652
[TBL] [Abstract][Full Text] [Related]
5. Recognition of xeno-(HLA, SLA) major histocompatibility complex antigens by mouse cytotoxic T cells is not H-2 restricted: a study with transgenic mice.
Kievits F; Wijffels J; Lokhorst W; Ivanyi P
Proc Natl Acad Sci U S A; 1989 Jan; 86(2):617-20. PubMed ID: 2783490
[TBL] [Abstract][Full Text] [Related]
6. Convergence of Targeted and Immune Therapies for the Treatment of Oncogene-Driven Cancers.
Cox AD; Ting JP; Der CJ
Cancer Discov; 2023 Jan; 13(1):19-22. PubMed ID: 36620884
[TBL] [Abstract][Full Text] [Related]
7. Carrier-independent hapten recognition and promiscuous MHC restriction by CD4 T cells induced by trinitrophenylated peptides.
Kohler J; Hartmann U; Grimm R; Pflugfelder U; Weltzien HU
J Immunol; 1997 Jan; 158(2):591-7. PubMed ID: 8992972
[TBL] [Abstract][Full Text] [Related]
8. Allergy to antibiotics: T-cell recognition of amoxicillin is HLA-DR restricted and does not require antigen processing.
Horton H; Weston SD; Hewitt CR
Allergy; 1998 Jan; 53(1):83-8. PubMed ID: 9491234
[TBL] [Abstract][Full Text] [Related]
9. Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens.
Khodadoust MS; Olsson N; Wagar LE; Haabeth OA; Chen B; Swaminathan K; Rawson K; Liu CL; Steiner D; Lund P; Rao S; Zhang L; Marceau C; Stehr H; Newman AM; Czerwinski DK; Carlton VE; Moorhead M; Faham M; Kohrt HE; Carette J; Green MR; Davis MM; Levy R; Elias JE; Alizadeh AA
Nature; 2017 Mar; 543(7647):723-727. PubMed ID: 28329770
[TBL] [Abstract][Full Text] [Related]
10. MHC-II neoantigens shape tumour immunity and response to immunotherapy.
Alspach E; Lussier DM; Miceli AP; Kizhvatov I; DuPage M; Luoma AM; Meng W; Lichti CF; Esaulova E; Vomund AN; Runci D; Ward JP; Gubin MM; Medrano RFV; Arthur CD; White JM; Sheehan KCF; Chen A; Wucherpfennig KW; Jacks T; Unanue ER; Artyomov MN; Schreiber RD
Nature; 2019 Oct; 574(7780):696-701. PubMed ID: 31645760
[TBL] [Abstract][Full Text] [Related]
11. Immunogenic peptide discovery in cancer genomes.
Snyder A; Chan TA
Curr Opin Genet Dev; 2015 Feb; 30():7-16. PubMed ID: 25588790
[TBL] [Abstract][Full Text] [Related]
12. Evidence for cytotoxic T lymphocyte response against human lung cancer: reconstitution of antigenic epitope with peptide eluted from lung adenocarcinoma MHC class I.
Calhoun RF; Naziruddin B; Enriquez-Rincon F; Duffy BF; Ritter JM; Sundaresan S; Patterson GA; Cooper JD; Mohanakumar T
Surgery; 2000 Jul; 128(1):76-85. PubMed ID: 10876189
[TBL] [Abstract][Full Text] [Related]
13. Engineering chimeric human and mouse major histocompatibility complex (MHC) class I tetramers for the production of T-cell receptor (TCR) mimic antibodies.
Li D; Bentley C; Yates J; Salimi M; Greig J; Wiblin S; Hassanali T; Banham AH
PLoS One; 2017; 12(4):e0176642. PubMed ID: 28448627
[TBL] [Abstract][Full Text] [Related]
14. Immune-based mutation classification enables neoantigen prioritization and immune feature discovery in cancer immunotherapy.
Bai P; Li Y; Zhou Q; Xia J; Wei PC; Deng H; Wu M; Chan SK; Kappler JW; Zhou Y; Tran E; Marrack P; Yin L
Oncoimmunology; 2021 Jan; 10(1):1868130. PubMed ID: 33537173
[TBL] [Abstract][Full Text] [Related]
15. An Integrated Genomic, Proteomic, and Immunopeptidomic Approach to Discover Treatment-Induced Neoantigens.
Olsson N; Heberling ML; Zhang L; Jhunjhunwala S; Phung QT; Lin S; Anania VG; Lill JR; Elias JE
Front Immunol; 2021; 12():662443. PubMed ID: 33936100
[TBL] [Abstract][Full Text] [Related]
16. HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model.
Schrörs B; Lübcke S; Lennerz V; Fatho M; Bicker A; Wölfel C; Derigs P; Hankeln T; Schadendorf D; Paschen A; Wölfel T
Oncotarget; 2017 Apr; 8(17):28312-28327. PubMed ID: 28423700
[TBL] [Abstract][Full Text] [Related]
17. A machine learning model for ranking candidate HLA class I neoantigens based on known neoepitopes from multiple human tumor types.
Gartner JJ; Parkhurst MR; Gros A; Tran E; Jafferji MS; Copeland A; Hanada KI; Zacharakis N; Lalani A; Krishna S; Sachs A; Prickett TD; Li YF; Florentin M; Kivitz S; Chatmon SC; Rosenberg SA; Robbins PF
Nat Cancer; 2021 May; 2(5):563-574. PubMed ID: 34927080
[TBL] [Abstract][Full Text] [Related]
18. Characterizing neoantigens for personalized cancer immunotherapy.
Capietto AH; Jhunjhunwala S; Delamarre L
Curr Opin Immunol; 2017 Jun; 46():58-65. PubMed ID: 28478383
[TBL] [Abstract][Full Text] [Related]
19. Identification of MHC class II restricted T-cell-mediated reactivity against MHC class I binding Mycobacterium tuberculosis peptides.
Wang M; Tang ST; Stryhn A; Justesen S; Larsen MV; Dziegiel MH; Lewinsohn DM; Buus S; Lund O; Claesson MH
Immunology; 2011 Apr; 132(4):482-91. PubMed ID: 21294723
[TBL] [Abstract][Full Text] [Related]
20. TEIPP antigens for T-cell based immunotherapy of immune-edited HLA class I
Marijt KA; Doorduijn EM; van Hall T
Mol Immunol; 2019 Sep; 113():43-49. PubMed ID: 29627136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
